Beta Bionics, Inc. BBNX
Nov 4, 2026, 1:11 PM EST
- YTD
- -46.57%
- 1 year
- -41.46%
- Market cap
- 884.01M
- Revenue (ttm)
- 119.01M
- Profit margin
- -61.31%
- EPS (ttm)
- -1.83
- Shares out
- 53.95M
- Forward P/E
- -9.90
- YTD return
- -46.57%
- 1-year return
- -41.46%
- Volume
- 371.91K
- Avg volume
- 1.21M
- Open
- 15.18
- Previous close
- 15.10
- Day's range
- 15.18 – 16.84
- 52-week range
- 8.80 – 32.71
- Price target
- 24.24 (+48.9%)
- Earnings date
- Feb 16, 2027
30m -4.61 (-22.00%)
Key statistics
- Enterprise value
- 748.76M
- PEG ratio
- 0.00
- Price / sales
- 9.70
- Price / book
- 3.75
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 37.80%
- Free cash flow
- -40.29M
- Total cash
- 180.49M
- Total debt
- 6.51M
- Return on equity
- -26.16%
- Short % of float
- 11.25%
- 50-day average
- 19.16
- 200-day average
- 14.81
Analyst view
- Target (low)
- 16.00
- Target (mean)
- 24.24
- Target (high)
- 30.40
- Strong buy2
- Buy9
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 16, 2027
Expected Feb 16, 2027. Consensus EPS estimate -0.51333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 16, 2027 | Dec 30, 2026 | -0.49 | — | — | — |
| Oct 27, 2026 | Sep 30, 2026 | -0.52334 | -0.52 | 0.00 | +0.64% |
| Jul 29, 2026 | Jun 30, 2026 | -0.58103 | -0.53 | +0.05 | +8.78% |
| Apr 21, 2026 | Mar 31, 2026 | -0.53 | -0.49 | +0.04 | +7.55% |
| Feb 17, 2026 | Dec 31, 2025 | -0.42 | -0.30 | +0.12 | +28.57% |
| Oct 28, 2025 | Sep 30, 2025 | -0.45 | -0.33 | +0.12 | +26.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | Jefferies | init | — | Buy |
| Sep 24, 2026 | Truist Securities | main | Buy | Buy |
| Sep 23, 2026 | Wells Fargo | init | — | Overweight |
| Sep 15, 2026 | B of A Securities | main | Neutral | Neutral |
| Sep 15, 2026 | Truist Securities | reit | Buy | Buy |
| Sep 15, 2026 | Baird | main | Neutral | Neutral |
About Beta Bionics, Inc.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- betabionics.com
News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines – BBNX 
BBNX Deadline: BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit 
BBNX Deadline Today: Rosen Law Firm Urges Beta Bionics, Inc. (NASDAQ: BBNX) Stockholders to Contact the Firm for Information About Their Rights 
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 3, 2026 in Beta Bionics, Inc. Lawsuit - BBNX 
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Beta Bionics (NASDAQ: BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026 
Beta Bionics, Inc. (NASDAQ:BBNX) SHAREHOLDER ALERT: Investors With Losses May Seek to Lead the Class Action in Beta Bionics, Inc. Securities Lawsuit - Contact Portnoy Law Firm 
Beta Bionics Announces Participation at Upcoming Investor Conferences 
BBNX FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX 
BBNX FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX 
BBNX FINAL DEADLINE ALERT: Beta Bionics Investors with Losses Encouraged to Contact Hagens Berman Before Nov. 3rd Deadline in Securities Class Action
Your note
Sign in to keep a note on BBNX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARNEY SEAN D | Director | Stock Award(Grant) | May 20, 2026 | 32,209 |
| DEAREN DANNY L | Director | Stock Award(Grant) | May 20, 2026 | 32,209 |
| FEIDER STEPHEN | Chief Financial Officer | Sale | Sep 1, 2026 | 159,378 |
| HOPMAN MARK | Officer | Sale | Sep 30, 2026 | 56,109 |
| MENSINGER MIKE | Officer | Sale | Sep 15, 2026 | 177,390 |
| MICHEL GERARD J | Director | Stock Award(Grant) | May 20, 2026 | 33,509 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Eventide Asset Management LLC | 13.90% | 6,253,673 | 133.77M | Jun 29, 2026 |
| Soleus Capital Management, L.P. | 9.77% | 4,393,714 | 93.98M | Jun 29, 2026 |
| Morgan Stanley | 9.48% | 4,266,822 | 91.27M | Jun 29, 2026 |
| Sands Capital Alternatives, LLC | 8.24% | 3,708,043 | 79.32M | Jun 29, 2026 |
| Blackrock Inc. | 7.42% | 3,340,171 | 71.45M | Jun 29, 2026 |
| Point72 Asset Management, L.P. | 5.01% | 2,254,683 | 48.23M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST-Eventide Gilead Fund | 8.86% | 3,983,917 | 85.22M | Jun 29, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 4.56% | 2,052,176 | 43.90M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.83% | 1,272,504 | 27.22M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.35% | 1,055,217 | 22.57M | Sep 29, 2026 |
| Bruce Fund, Inc.-BRUCE FUND | 1.48% | 665,700 | 14.24M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.04% | 469,615 | 10.05M | Jun 29, 2026 |